Gastroenterología y Hepatología (English Edition)最新文献

{"title":"Artificial intelligence-assisted identification and retrieval of chronic hepatitis C patients lost to follow-up in the health area of Pontevedra and O Salnés (Spain)","authors":"Pablo Parada Vázquez ,&nbsp;Santiago Pérez-Cachafeiro ,&nbsp;Belén Castiñeira Domínguez ,&nbsp;Juan Manuel González-Pérez ,&nbsp;José Manuel Mera Calviño ,&nbsp;Raquel Souto-Rodríguez ,&nbsp;Yolanda Falagán Cachafeiro ,&nbsp;Indhira Pérez-Medrano ,&nbsp;Nuria Vázquez-Temprano ,&nbsp;Matilde Trigo ,&nbsp;Alba Carrodeguas ,&nbsp;José Luis González-Sánchez ,&nbsp;Carmen Durán-Parrondo ,&nbsp;Juan Turnes","doi":"10.1016/j.gastre.2024.502226","DOIUrl":"10.1016/j.gastre.2024.502226","url":null,"abstract":"<div><h3>Objective</h3><div>Direct-acting antivirals (DAAs) to treat hepatitis C virus (HCV) infection offer an opportunity to eliminate the disease. This study aimed to identify and relink to care HCV patients previously lost to medical follow-up in the health area of Pontevedra and O Salnés (Spain) using an artificial intelligence-assisted system.</div></div><div><h3>Patients and methods</h3><div>Active retrospective search of previously diagnosed HCV cases recorded in the Galician Health Service proprietary health information exchange database using the Herramientas para la EXplotación de la INformación (HEXIN) application.</div></div><div><h3>Results and conclusions</h3><div>Out of 99 lost patients identified, 64 (64.6%) were retrieved. Of these, 62 (96.88%) initiated DAA treatment and 54 patients (87.1%) achieved a sustained virological response. Mean time from HCV diagnosis was over 10 years. Main reasons for loss to follow-up were fear of possible adverse effects of treatment (30%) and mobility impediments (21%). Among the retrieved patients, almost one in three presented advanced liver fibrosis (F3) or cirrhosis (F4) at evaluation. In sum, HCV patients lost to follow-up can be retrieved by screening past laboratory records. This strategy promotes the achievement of HCV elimination goals.</div></div>","PeriodicalId":100569,"journal":{"name":"Gastroenterología y Hepatología (English Edition)","volume":"48 1","pages":"Article 502226"},"PeriodicalIF":0.0,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143140250","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Assessment of the quality of life of patients with inflammatory bowel disease","authors":"María del Mar Calvo Bernal ,&nbsp;Elena Pérez Campos ,&nbsp;Adrián Aparicio Mota ,&nbsp;Álvaro Hernández Martínez","doi":"10.1016/j.gastre.2024.502192","DOIUrl":"10.1016/j.gastre.2024.502192","url":null,"abstract":"<div><h3>Introduction</h3><div>Ulcerative colitis (UC) and Crohn's disease (CD) are diseases that cause a significant impact on patients' quality of life.</div><div>The aim of this study is to assess the impact of inflammatory bowel disease (IBD) on health-related quality of life (HRQoL).</div></div><div><h3>Material and methods</h3><div>Observational, descriptive, cross-sectional study, carried out at Torrecárdenas Hospital (Almería). Patients over 14 years of age diagnosed with CD or UC were included. For the assessment of HRQoL, the reduced 9-item IBDQ-9 questionnaire was used.</div></div><div><h3>Results</h3><div>106 patients with a mean age of 44 years were included, with a female predominance. Forty-five percent of the patients in the sample had UC compared to 55% with CD. Of the patients, 69.8% were in clinical remission. The median questionnaire score was 60.8 points out of 100. Statistically significant differences were observed between sexes, with worse HRQoL for females. No differences were observed between patients with UC and CD. Differences were also detected between patients who underwent surgery and those who did not. A negative association was observed between the number of flares and the questionnaire score.</div></div><div><h3>Conclusions</h3><div>In our study population, there is an acceptable HRQoL, with no differences observed between CD and UC. Female sex, absence of clinical remission, number of previous outbreaks, and surgery have a negative association with HRQoL.</div></div>","PeriodicalId":100569,"journal":{"name":"Gastroenterología y Hepatología (English Edition)","volume":"48 1","pages":"Article 502192"},"PeriodicalIF":0.0,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143140415","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Increased arterial stiffness in Crohn's disease: Prevalence, associated factors and impact of anti-TNF therapy","authors":"Mahrez Fissah ,&nbsp;Adel Rechach ,&nbsp;Meriem Charifi ,&nbsp;Farouk Menzou ,&nbsp;Said Taharboucht ,&nbsp;Messaouda Djouhri ,&nbsp;Leila Talbi ,&nbsp;Nadia Touati ,&nbsp;Lamine Atif ,&nbsp;Mehdi Rabhia ,&nbsp;Ahcene Chibane","doi":"10.1016/j.gastre.2024.502252","DOIUrl":"10.1016/j.gastre.2024.502252","url":null,"abstract":"<div><h3>Introduction</h3><div>Recent studies have demonstrated the growing interest in cardiovascular risk in Crohn's disease (CD), the aim of our work is to highlight the need for research into the frequency of arterial stiffness (AS) and its link with certain associated factors, particularly those related to inflammation.</div></div><div><h3>Materials and methods</h3><div>This was a cross-sectional observational study involving 118 patients with CD. Pulse wave velocity (PWV) measured by applanation tonometry was the criterion for calculating AS, the study also investigated the association of AS especially the indicators of inflammation, as well as the impact of anti-TNF alpha therapy on AS.</div></div><div><h3>Results</h3><div>The prevalence of AS, after adjustment for age and blood pressure level reached more than a quarter of patients compared to the cardiovascular risk which was low. The factors that were strongly associated with AS were age, systolic and diastolic blood pressure. Two parameters related to inflammation emerged as having a highly significant link after multivariate analysis: recurrence in the last year and length of disease with a <em>p</em> <!-->=<!--> <!-->0.008, and an OR of 5 and 9 successively. Patients treated with anti-TNF alpha had a significant reduction in PWV.</div></div><div><h3>Conclusion</h3><div>The prevalence of AS reached more than a quarter of patients with CD, the duration and recurrence rate of CD appear to be factors linked to inflammation. Treatment with anti-TNF alpha seems to slow down PWV in these patients.</div></div>","PeriodicalId":100569,"journal":{"name":"Gastroenterología y Hepatología (English Edition)","volume":"48 1","pages":"Article 502252"},"PeriodicalIF":0.0,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143140249","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Combined biologic treatment in patient with chronic spontaneous urticaria and Crohn’s disease","authors":"Alejandro García Martínez ,&nbsp;María del Pilar Lobato de la Sierra ,&nbsp;Teresa Castro Aguilar-Tablada","doi":"10.1016/j.gastre.2024.502213","DOIUrl":"10.1016/j.gastre.2024.502213","url":null,"abstract":"","PeriodicalId":100569,"journal":{"name":"Gastroenterología y Hepatología (English Edition)","volume":"48 1","pages":"Article 502213"},"PeriodicalIF":0.0,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143140421","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Heterotaxia syndrome: when almost nothing is as it should be","authors":"Luisa Adán-Merino ,&nbsp;Francisco Garrido Gallego ,&nbsp;Rodrigo Pastorín-Salis ,&nbsp;Ángel Ponferrada-Díaz","doi":"10.1016/j.gastre.2024.502233","DOIUrl":"10.1016/j.gastre.2024.502233","url":null,"abstract":"","PeriodicalId":100569,"journal":{"name":"Gastroenterología y Hepatología (English Edition)","volume":"48 1","pages":"Article 502233"},"PeriodicalIF":0.0,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143140427","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Gastric antral ectasia and diaphragmatic hernia: A rare cause of iron deficiency anemia","authors":"Ana Lancho Muñoz,&nbsp;Patricia Abellán Alfocea,&nbsp;Eduardo Redondo Cerezo","doi":"10.1016/j.gastre.2024.502209","DOIUrl":"10.1016/j.gastre.2024.502209","url":null,"abstract":"","PeriodicalId":100569,"journal":{"name":"Gastroenterología y Hepatología (English Edition)","volume":"48 1","pages":"Article 502209"},"PeriodicalIF":0.0,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143139830","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Vaccine adherence and adverse events of the SARS-COV vaccine in patients with inflammatory bowel disease","authors":"Francisca Isabelle da Silva e Sousa ,&nbsp;Raiza Lima Silva ,&nbsp;Cezar Nilton Rabelo Lemos Filho ,&nbsp;Maria Tereza Oliveira Pereira Santos ,&nbsp;Luiz Eduardo Soares Martins ,&nbsp;Thais Carvalho de Abreu ,&nbsp;Leonardo Freire Alves Nogueira ,&nbsp;Sâmya Correia Marques ,&nbsp;Marcellus Henrique Loiola Ponte de Souza ,&nbsp;Lucia Libanez Bessa Campelo Braga","doi":"10.1016/j.gastre.2024.502202","DOIUrl":"10.1016/j.gastre.2024.502202","url":null,"abstract":"<div><h3>Objective</h3><div>To assess adherence to and the adverse effects of the SARS-COV vaccine in patients with inflammatory bowel disease (IBD).</div></div><div><h3>Patients and methods</h3><div>This is an observational, analytical, cross-sectional study. Sociodemographic and clinical data, SARS-COV vaccine data, medications for IBD with use during the vaccination period, and adverse events during the vaccination period were collected. Carried out logistic regressions with robust variance estimation to estimate the odds ratio with the respective 95% confidence intervals (95%CI) to assess the factors associated with non-serious adverse effects following vaccine doses as outcome variables.</div></div><div><h3>Results</h3><div>194 patients participated, with vaccine compliance of 78.3% for three doses of any vaccine (<em>n</em> <!-->=<!--> <!-->152). Local symptoms and mild systemic symptoms predominated, regardless of the type of vaccine. The first dose of the SARS-COV vaccine with AstraZeneca had a higher percentage of patients with vaccine symptoms. AstraZeneca vaccine increased the chance of non-serious adverse effects in IBD patients by 2.65 times (95% CI: 1.38–5.08; <em>p</em> <!-->=<!--> <!-->0.003), regardless of age, gender, physical activity, excess weight, use of disease-modifying drugs, immunobiological and corticosteroids. CoronaVac vaccine was associated with asymptomatic patients at the first dose and reduced the chance of adverse effects by 0.28 times (OR: 0.284; 95%CI: 0.13–0.62; <em>p</em> <!-->=<!--> <!-->0.002).</div></div><div><h3>Conclusion</h3><div>Local symptoms and mild systemic symptoms predominated, regardless of the type of vaccine. Using CoronaVac in the first dose reduced the chances of adverse effects, while AstraZeneca increased the risk of adverse effects.</div></div>","PeriodicalId":100569,"journal":{"name":"Gastroenterología y Hepatología (English Edition)","volume":"48 1","pages":"Article 502202"},"PeriodicalIF":0.0,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143139835","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Portal hypertension: recommendations for diagnosis and treatment. Consensus document sponsored by the Spanish Association for the Study of the Liver (AEEH) and the Biomedical Research Network Centre for Liver and Digestive Diseases (CIBERehd)","authors":"Agustín Albillos ,&nbsp;Rafael Bañares ,&nbsp;Virginia Hernández-Gea ,&nbsp;on behalf of the Spanish Portal Hypertension Consensus group","doi":"10.1016/j.gastre.2024.502208","DOIUrl":"10.1016/j.gastre.2024.502208","url":null,"abstract":"<div><div>Portal hypertension is a hemodynamic abnormality that complicates the course of cirrhosis, as well as other diseases that affect the portal venous circulation. The development of portal hypertension compromises prognosis, especially when it rises above a certain threshold known as clinically significant portal hypertension (CSPH). In the consensus conference on Portal Hypertension promoted by the Spanish Association for the Study of the Liver and the Hepatic and Digestive diseases area of the Biomedical Research Networking Center (CIBERehd), different aspects of the diagnosis and treatment of portal hypertension caused by cirrhosis or other diseases were discussed. The outcome of this discussion was a set of recommendations that achieved varying degrees of consensus among panelists and are reflected in this consensus document. The six areas under discussion were: the relevance of clinically significant portal hypertension and the non-invasive methods used for its diagnosis and that of cirrhosis, the prevention of the first episode of decompensation and its recurrence, the treatment of acute variceal bleeding and other complications of portal hypertension, the indications for the use of TIPS, and finally, the diagnosis and treatment of liver vascular diseases.</div></div>","PeriodicalId":100569,"journal":{"name":"Gastroenterología y Hepatología (English Edition)","volume":"48 1","pages":"Article 502208"},"PeriodicalIF":0.0,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143140251","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Treatment of severe hypertriglyceridemia through therapeutic plasma exchange in patients with acute pancreatitis or at risk of developing it","authors":"Eva Marín-Serrano ,&nbsp;Ana Kerguelen Fuentes ,&nbsp;Rubén Fernández-Martos ,&nbsp;José Mostaza Prieto ,&nbsp;Aurora Viejo Llorente ,&nbsp;Ana Barbado Cano ,&nbsp;Pedro Luis Martínez Hernández ,&nbsp;María Dolores Martín-Arranz","doi":"10.1016/j.gastre.2024.502229","DOIUrl":"10.1016/j.gastre.2024.502229","url":null,"abstract":"<div><h3>Introduction and objectives</h3><div>TPE drastically reduces serum triglyceride (sTG), but its role in the treatment of hypertriglyceridemia-induced acute pancreatitis (HTG-AP) or at risk of developing it, is not well established. The objectives were to assess the effectiveness and safety of TPE in the treatment of severe HTG (sHTG), as well as to evaluate the severity of HTG-AP treated with TPE.</div></div><div><h3>Materials and methods</h3><div>Observational-retrospective-single-center study, in which a descriptive analysis of sHTG treated with TPE was conducted, with the aim of treating HTG-AP or preventing its recurrence. TPE was performed if sTG≥ 1000<!--> <!-->mg/dl after 24<!--> <!-->hours of admission.</div></div><div><h3>Results</h3><div>42 TPE were performed to treat 35 sHTG in 23 patients: 29 HTG-AP, and 6 sHTG with previous HTG-AP. Among the patients, 37% (13/55) were women, with 37<!--> <!-->±<!--> <!-->14 years-old, 74.3% had normal BMI (25/35), 34% (12/35) were drinking &gt;40<!--> <!-->g/alcohol/day and 54% (19/35) were diabetics. TPE significantly reduced the baseline sTG (4425<!--> <!-->±<!--> <!-->2782<!--> <!-->mg/dl vs. 709<!--> <!-->±<!--> <!-->353<!--> <!-->mg/dL, p<!--> <!-->&lt;<!--> <!-->0.001) in a single session, achieving a mean percentage reduction of 79<!--> <!-->±<!--> <!-->13%; 20% (7/35) of sHTG cases required two TPE sessions to reduce sTG to &lt;1000<!--> <!-->mg/dL. Adverse effects were reported in 4/42 TPE sessions (9,5%). sHTG-AP was observed in 3% of cases (1/29), and there were no deaths. sTG at 24<!--> <!-->h of admission showed no relation with the severity of APs.</div></div><div><h3>Conclusion</h3><div>The treatment of sHTG with TPE, with the aim of treating HTG-AP or preventing its recurrence, reduces sTG quickly and safety.</div></div>","PeriodicalId":100569,"journal":{"name":"Gastroenterología y Hepatología (English Edition)","volume":"48 1","pages":"Article 502229"},"PeriodicalIF":0.0,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143139834","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Thromboembolic phenomena in inflammatory bowel disease and risk with JAK inhibitor treatments","authors":"José Luis Rueda García ,&nbsp;José Manuel Benitez ,&nbsp;Iria Baston Rey ,&nbsp;Margalida Calafat Sard ,&nbsp;Cristina Suárez Ferrer","doi":"10.1016/j.gastre.2024.502257","DOIUrl":"10.1016/j.gastre.2024.502257","url":null,"abstract":"","PeriodicalId":100569,"journal":{"name":"Gastroenterología y Hepatología (English Edition)","volume":"48 1","pages":"Article 502257"},"PeriodicalIF":0.0,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143140244","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}